Aronora Overview

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series A
  • (In Progress)

  • Latest Deal Amount
  • $125M

  • Investors
  • 6

Aronora General Information

Description

Developer of therapeutics designed to treat thrombotic and thrombo-inflammatory diseases and prevent pathological blood clot formation. The company offers drug candidates that target clot formation without increasing bleeding risk, enabling patients with cardiovascular and thrombotic disorders to access safer treatment options and improve clinical outcomes.

Contact Information

Website
www.aronora.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1818 Southwest 4th Avenue
  • Suite 102
  • Portland, OR 97201
  • United States
+1 (503)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 1818 Southwest 4th Avenue
  • Suite 102
  • Portland, OR 97201
  • United States
+1 (503)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aronora Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
19. Later Stage VC (Series A) 01-Jul-2026 $125M In Progress Clinical Trials - Phase 2
18. Later Stage VC 05-Jul-2023 Completed Clinical Trials - Phase 2
17. Grant 22-Apr-2022 Completed Clinical Trials - Phase 2
16. Grant 01-Jan-2020 Completed Clinical Trials - Phase 2
15. Grant 15-May-2019 Completed Startup
14. Grant 15-May-2019 Completed Startup
13. Grant 05-Jul-2018 Completed Startup
12. Grant 13-Sep-2017 Completed Startup
11. Grant 15-May-2017 $2.36M Completed Startup
10. Grant 01-Aug-2016 $953K Completed Startup
To view Aronora’s complete valuation and funding history, request access »

Aronora Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutics designed to treat thrombotic and thrombo-inflammatory diseases and prevent pathological blood
Drug Discovery
Portland, OR
9 As of 2026

East Hanover, NJ
 

King Of Prussia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aronora Competitors (12)

One of Aronora’s 12 competitors is Anthos Therapeutics, a Formerly PE-Backed company based in East Hanover, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anthos Therapeutics Formerly PE-Backed East Hanover, NJ
CSL Behring Corporation King Of Prussia, PA
Basking Biosciences Venture Capital-Backed Cary, NC
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Gilead Formerly VC-backed Foster City, CA
You’re viewing 5 of 12 competitors. Get the full list »

Aronora Patents

  • 42

    Total Documents Applications and Grants

  • Total Patents Families

  • 16

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

Aronora Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220089777-A1 Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effect and uses thereof Pending 21-Jan-2019
AU-2020211905-A1 Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof Active 21-Jan-2019
AU-2020211905-B2 Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof Active 21-Jan-2019
CA-3125303-A1 Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof Pending 21-Jan-2019
EP-3914624-A1 Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof Pending 21-Jan-2019 C07K16/36
To view Aronora’s complete patent history, request access »

Aronora Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aronora Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
NYBC Ventures Corporate Venture Capital
National Institutes of Arthritis and Musculoskeletal Diseases Not-For-Profit Venture Capital
National Institutes of Health Government
National Institutes of Neurological Disorders and Stroke Government
National Institute for Allergy and Infectious Disease Government
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Aronora FAQs

  • Where is Aronora headquartered?

    Aronora is headquartered in Portland, OR.

  • What is the size of Aronora?

    Aronora has 9 total employees.

  • What industry is Aronora in?

    Aronora’s primary industry is Drug Discovery.

  • Is Aronora a private or public company?

    Aronora is a Private company.

  • What is Aronora’s current revenue?

    The current revenue for Aronora is .

  • How much funding has Aronora raised over time?

    Aronora has raised $2M.

  • Who are Aronora’s investors?

    NYBC Ventures, National Institutes of Arthritis and Musculoskeletal Diseases, National Institutes of Health, National Institutes of Neurological Disorders and Stroke, and National Institute for Allergy and Infectious Disease are 5 of 6 investors who have invested in Aronora.

  • Who are Aronora’s competitors?

    Anthos Therapeutics, CSL Behring, Basking Biosciences, CytomX Therapeutics, and Gilead are some of the 12 competitors of Aronora.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process